A noninvasive blood test to detect genetic material shed by tumors may help clinicians identify adverse events related to treatment with immune checkpoint inhibitor drugs, investigators at the Johns ...
1don MSN
Mitotic stopwatch pathway shows how cancer loses its sense of time to avoid stress responses
When cell division (mitosis) takes too long, it can be a sign that something is wrong with the cells, for example, DNA damage ...
Results from a VHIO-led study show that MYC targeting by Omomyc induces tumor DNA damage in patient-derived preclinical ...
Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (“Rakovina” or the “Company”), a biopharmaceutical company advancing innovative cancer therapies through artificial intelligence (AI)-powered drug ...
This SNO 2025 presentation represents the second abstract from Rakovina Therapeutics at the conference and reflects the Company’s ongoing research efforts in the field of DNA-damage-response (DDR) ...
Findings from a preclinical study demonstrate that Omomyc—the only direct MYC inhibitor to have successfully completed a ...
On November 18, 2025, the Company announced that its President & CSO, Prof. Mads Daugaard, has been invited to present and ...
Detailed price information for Rakovina Therapeutics Inc (RKV-X) from The Globe and Mail including charting and trades.
Age related decline in female fertility remains one of the most urgent challenges facing reproductive medicine today. The decline affects both the number and the quality of oocytes, which reduces chan ...
New tools that create ultra-precise maps of our tissues are transforming our ability to diagnose and cure once-fatal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback